ArticleIranian biomedical journal2026
Inverse GAS5-SFXN1 Correlation in Triple-Negative Breast Cancer: Insights from Bioinformatics and Tissue Expression Analysis.
Article in Iranian biomedical journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Triple-negative breast cancer (TNBC) is an aggressive subtype with limited therapeutic options. Given the involvement of long non-coding RNAs, like GAS5, in cancer progression, this study aimed to identify GAS5-associated target genes through breast cancer databases and evaluate the expression levels of GAS5 and SFXN1 (as a potential target) in TNBC tissues. Methods: After predicting putative GAS5 targets via StarBase, they were validated through TCGA and GEPIA2. RT-qPCR was then performed to examine GAS5 and SFXN1 expression in 18 tumor and 15 adjacent normal samples. Gene expression levels were quantified using the fold-change method, and statistical analyses were performed using linear mixed models, one-sample t-tests, and Spearman's correlation. Results: Bioinformatics analyses revealed significant differential expression of SFXN1 in the TCGA and GEPIA2 databases. In the experimental validation phase, the mean Log2FC values for GAS5 and SFXN1 in tumor samples were 0.235 and -0.450, respectively. Neither gene showed a statistically significant difference between tumor and normal tissues using the t-test (GAS5: p = 0.650; SFXN1: p = 0.458). The linear mixed model also revealed no significant difference for either gene in the same comparison. Spearman's correlation, however, demonstrated a significant negative correlation between GAS5 and SFXN1 expression (r = -0.479; p = 0.049). Conclusion: While GAS5 and SFXN1 were not differentially expressed in TNBC tissues, their significant inverse correlation suggests a potential association that may contribute to the molecular networks underlying TNBC pathogenesis. Further functional studies are warranted to clarify this relationship. Any diagnostic or therapeutic implications remain speculative at this stage.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.